BDTX vs. GRPH, MOLN, GNFT, FUSN, ERYP, TCRX, OMGA, INMB, TALS, and ORTX
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Graphite Bio (GRPH), Molecular Partners (MOLN), Genfit (GNFT), Fusion Pharmaceuticals (FUSN), ERYTECH Pharma (ERYP), TScan Therapeutics (TCRX), Omega Therapeutics (OMGA), INmune Bio (INMB), Talaris Therapeutics (TALS), and Orchard Therapeutics (ORTX). These companies are all part of the "biological products, except diagnostic" industry.
Black Diamond Therapeutics (NASDAQ:BDTX) and Graphite Bio (NASDAQ:GRPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
Black Diamond Therapeutics received 22 more outperform votes than Graphite Bio when rated by MarketBeat users. Likewise, 60.71% of users gave Black Diamond Therapeutics an outperform vote while only 37.50% of users gave Graphite Bio an outperform vote.
In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Graphite Bio. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for Graphite Bio. Graphite Bio's average media sentiment score of 0.29 beat Black Diamond Therapeutics' score of -1.00 indicating that Graphite Bio is being referred to more favorably in the news media.
Black Diamond Therapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500. Comparatively, Graphite Bio has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.
Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Graphite Bio, indicating that it is currently the more affordable of the two stocks.
Graphite Bio's return on equity of -31.89% beat Black Diamond Therapeutics' return on equity.
Black Diamond Therapeutics currently has a consensus target price of $10.50, indicating a potential upside of 311.76%. Graphite Bio has a consensus target price of $3.33, indicating a potential upside of 35.50%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than Graphite Bio.
54.3% of Graphite Bio shares are held by institutional investors. 9.1% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 38.4% of Graphite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Black Diamond Therapeutics beats Graphite Bio on 9 of the 15 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
